3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Breast Neoplasms
15
Leukemia
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Leukemia, Myeloid, Chronic-Phase
10
Recurrence
8
Prostatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Lung Neoplasms
7
Neoplasm Metastasis
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Melanoma
5
Burkitt Lymphoma
5
Pancreatic Neoplasms
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Blast Crisis
4
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Neoplasms
3
Lymphoma
3
Gliosarcoma
3
Sarcoma
2
Salivary Gland Neoplasms
2
Rhabdomyosarcoma
2
Rectal Neoplasms
2
Polycythemia Vera
2
Oligodendroglioma
2
Multiple Myeloma
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
enzalutamide
3
pembrolizumab
1
nilutamide
1
bicalutamide
1
apalutamide
1
Vorinostat
1
Tamoxifen
1
Panobinostat
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Bulbo-Spinal Atrophy, X-Linked
×
Dasatinib
×
Clear all
NCT00918385
2014-10-29
ARS
Duke University
Phase 2
Terminated
57 enrolled
8 charts